Skip to main content
Erschienen in: Esophagus 2/2016

13.10.2015 | Original Article

A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan

verfasst von: Yasushi Toh, Yuko Kitagawa, Hiroyuki Kuwano, Motoyasu Kusano, Tsuneo Oyama, Manabu Muto, Hiroyuki Kato, Hiroya Takeuchi, Yuichiro Doki, Yoshio Naomoto, Kenji Nemoto, Hisahiro Matsubara, Tatsuya Miyazaki, Akio Yanagisawa, Takashi Uno, Ken Kato, Masahiro Yoshida, Hirofumi Kawakubo, Eisuke Booka

Erschienen in: Esophagus | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

There is a lack of critical evidence to justify the methods of follow-up after a curative esophagectomy or a complete response to definitive chemoradiotherapy (dCRT). Consequently, a wide variety of practices are in place throughout the world.

Methods

A questionnaire concerning follow-up protocols was sent via electronic email for a nation-wide survey of the 117 Japanese hospitals that are recognized by the Japan Esophageal Society as training facilities for certified esophageal surgeons. Seventy-seven hospitals responded to the questionnaire.

Results

Most hospitals follow their patients for at least 5 years after esophagectomy or dCRT, usually at a frequency of more than 4 times per year with clinical visits and physical examinations in the 1st and 2nd year after treatment. About 65–75 and 40 % of the hospitals continue the follow-up until the 7th and 10th year after treatment, respectively. Most hospitals measure CEA and SCC-Ag and almost all hospitals utilize CT scans of the cervix, chest and abdomen for the follow-up. Most of the hospitals reported performing an upper gastrointestinal endoscopy at least once per year until the 5th year after treatment, more frequently for post-dCRT patients than for post-esophagectomy patients. Other imaging modalities such as FDG-PET/CT, cervical and abdominal USs, and chest and abdominal X-rays were incorporated at much lower rates.

Conclusions

Follow-up protocols for patients who have been treated for esophageal cancer with curative intent vary among the hospitals in Japan. Based on these data, the most popular follow-up protocols in Japan are shown.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.CrossRefPubMed Abate E, DeMeester SR, Zehetner J, et al. Recurrence after esophagectomy for adenocarcinoma: defining optimal follow-up intervals and testing. J Am Coll Surg. 2010;210:428–35.CrossRefPubMed
2.
4.
Zurück zum Zitat Versteijne E, van Laarhoven HW, van Hooft JE, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus. 2015;28:453–9.CrossRefPubMed Versteijne E, van Laarhoven HW, van Hooft JE, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus. 2015;28:453–9.CrossRefPubMed
5.
Zurück zum Zitat Toh Y, Oki E, Minami K, et al. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37–43.CrossRef Toh Y, Oki E, Minami K, et al. Follow-up and recurrence after a curative esophagectomy for patients with esophageal cancer: the first indicators for recurrence and their prognostic values. Esophagus. 2010;7:37–43.CrossRef
6.
Zurück zum Zitat Antonowicz SS, Lorenzi B, Parker M, et al. Annual computed tomography scans do not improve outcomes following esophagectomy for cancer: a 10-year UK experience. Dis Esophagus. 2015;28:365–70.CrossRefPubMed Antonowicz SS, Lorenzi B, Parker M, et al. Annual computed tomography scans do not improve outcomes following esophagectomy for cancer: a 10-year UK experience. Dis Esophagus. 2015;28:365–70.CrossRefPubMed
7.
Zurück zum Zitat Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014;12:1139–44.PubMed Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw. 2014;12:1139–44.PubMed
8.
Zurück zum Zitat Peixoto RD, Lim HJ, Kim H, et al. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45:325–33.CrossRefPubMed Peixoto RD, Lim HJ, Kim H, et al. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer. 2014;45:325–33.CrossRefPubMed
9.
Zurück zum Zitat Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–702.CrossRefPubMed Ishikura S, Nihei K, Ohtsu A, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21:2697–702.CrossRefPubMed
10.
Zurück zum Zitat Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:194–227.PubMed Ajani JA, D’Amico TA, Almhanna K, et al. Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw. 2015;13:194–227.PubMed
11.
Zurück zum Zitat Stahl M, Budach W, Meyer HJ, et al. Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v46–9.CrossRefPubMed Stahl M, Budach W, Meyer HJ, et al. Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v46–9.CrossRefPubMed
12.
Zurück zum Zitat Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.CrossRefPubMedPubMedCentral Ando N, Ozawa S, Kitagawa Y, et al. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Japan Esophageal Society. Japanese Classification of Esophageal Cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef Japan Esophageal Society. Japanese Classification of Esophageal Cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef
14.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus. 2009;6:71–94.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus. 2009;6:71–94.CrossRef
15.
Zurück zum Zitat Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2006. Esophagus. 2014;11:21–47.CrossRef Tachimori Y, Ozawa S, Fujishiro M, et al. Comprehensive Registry of Esophageal Cancer in Japan, 2006. Esophagus. 2014;11:21–47.CrossRef
16.
Zurück zum Zitat Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39:1384–94.CrossRefPubMed Blazeby JM, Conroy T, Hammerlid E, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39:1384–94.CrossRefPubMed
17.
Zurück zum Zitat Darling G, Eton DT, Sulman J, et al. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006;107:854–63.CrossRefPubMed Darling G, Eton DT, Sulman J, et al. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006;107:854–63.CrossRefPubMed
18.
Zurück zum Zitat Hiyoshi Y, Morita M, Kawano H, et al. Clinical significance of surgical resection for the recurrence of esophageal cancer after radical esophagectomy. Ann Surg Oncol. 2015;22:240–6.CrossRefPubMed Hiyoshi Y, Morita M, Kawano H, et al. Clinical significance of surgical resection for the recurrence of esophageal cancer after radical esophagectomy. Ann Surg Oncol. 2015;22:240–6.CrossRefPubMed
19.
Zurück zum Zitat Schipper PH, Cassivi SD, Deschamps C, et al. Locally recurrent esophageal carcinoma: when is re-resection indicated? Ann Thorac Surg. 2005;80:1001–5.CrossRefPubMed Schipper PH, Cassivi SD, Deschamps C, et al. Locally recurrent esophageal carcinoma: when is re-resection indicated? Ann Thorac Surg. 2005;80:1001–5.CrossRefPubMed
20.
Zurück zum Zitat Kobayashi R, Yamashita H, Okuma K, et al. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus. 2014;27:72–8.CrossRefPubMed Kobayashi R, Yamashita H, Okuma K, et al. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus. 2014;27:72–8.CrossRefPubMed
21.
Zurück zum Zitat Zhu YL, Li Q, Gao JM, et al. A retrospective evaluation of radiotherapy for the treatment of local esophageal squamous cell carcinoma recurrence after initial complete surgical resection. J Investig Med. 2013;61:34–9.PubMed Zhu YL, Li Q, Gao JM, et al. A retrospective evaluation of radiotherapy for the treatment of local esophageal squamous cell carcinoma recurrence after initial complete surgical resection. J Investig Med. 2013;61:34–9.PubMed
22.
Zurück zum Zitat Ma X, Zhao K, Guo W, et al. Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22:624–9.CrossRefPubMed Ma X, Zhao K, Guo W, et al. Salvage lymphadenectomy versus salvage radiotherapy/chemoradiotherapy for recurrence in cervical lymph node after curative resection of esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22:624–9.CrossRefPubMed
23.
Zurück zum Zitat Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014;32:3400–5.CrossRefPubMedPubMedCentral Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014;32:3400–5.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Watanabe M, Mine S, Nishida K, et al. Salvage esophagectomy after definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: who really benefits from this high-risk surgery? Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4556-6. Watanabe M, Mine S, Nishida K, et al. Salvage esophagectomy after definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma: who really benefits from this high-risk surgery? Ann Surg Oncol. 2015. doi:10.​1245/​s10434-015-4556-6.
25.
Zurück zum Zitat Kato H, Fukuchi M, Miyazaki T, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25:3461–7.PubMed Kato H, Fukuchi M, Miyazaki T, et al. Classification of recurrent esophageal cancer after radical esophagectomy with two- or three-field lymphadenectomy. Anticancer Res. 2005;25:3461–7.PubMed
26.
Zurück zum Zitat Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.CrossRefPubMed Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.CrossRefPubMed
27.
Zurück zum Zitat Sato Y, Motoyama S, Maruyama K, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188–93.CrossRefPubMed Sato Y, Motoyama S, Maruyama K, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188–93.CrossRefPubMed
28.
Zurück zum Zitat Oki E, Morita M, Toh Y, et al. Gastric cancer in the reconstructed gastric tube after radical esophagectomy: a single-center experience. Surg Today. 2011;41:966–9.CrossRefPubMed Oki E, Morita M, Toh Y, et al. Gastric cancer in the reconstructed gastric tube after radical esophagectomy: a single-center experience. Surg Today. 2011;41:966–9.CrossRefPubMed
29.
Zurück zum Zitat Polinder S, Verschuur EM, Siersema PD, et al. Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer. Eur J Cancer. 2009;45:2110–5.CrossRefPubMed Polinder S, Verschuur EM, Siersema PD, et al. Cost comparison study of two different follow-up protocols after surgery for oesophageal cancer. Eur J Cancer. 2009;45:2110–5.CrossRefPubMed
30.
Zurück zum Zitat Blom RL, Nieuwkerk PT, van Heijl M, et al. Patient preferences in screening for recurrent disease after potentially curative esophagectomy. Dig Surg. 2012;29:206–12.CrossRefPubMed Blom RL, Nieuwkerk PT, van Heijl M, et al. Patient preferences in screening for recurrent disease after potentially curative esophagectomy. Dig Surg. 2012;29:206–12.CrossRefPubMed
Metadaten
Titel
A nation-wide survey of follow-up strategies for esophageal cancer patients after a curative esophagectomy or a complete response by definitive chemoradiotherapy in Japan
verfasst von
Yasushi Toh
Yuko Kitagawa
Hiroyuki Kuwano
Motoyasu Kusano
Tsuneo Oyama
Manabu Muto
Hiroyuki Kato
Hiroya Takeuchi
Yuichiro Doki
Yoshio Naomoto
Kenji Nemoto
Hisahiro Matsubara
Tatsuya Miyazaki
Akio Yanagisawa
Takashi Uno
Ken Kato
Masahiro Yoshida
Hirofumi Kawakubo
Eisuke Booka
Publikationsdatum
13.10.2015
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 2/2016
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-015-0511-7

Weitere Artikel der Ausgabe 2/2016

Esophagus 2/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.